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Renal cell carcinoma (RCC) is the most common 
malignant kidney tumor in adults. It stands for approxi-
mately 3% of all human malignancies. Among cancers 
of the urinary system, RCC is associated with the worst 
clinical outcome [1]. The incidence of RCC is increas-
ing and it is estimated that RCC accounts worldwide 
for 95,000 cancer-related deaths per year [2].
At present, surgical resection is the most effective 
treatment for localized RCC tumors, but no satisfac-
tory treatment is available for patients with advanced-
stage tumor. Some therapies for RCCs have achieved 
a response rate of 20%, but severe adverse reactions 
are frequent and prognosis for patients does not 
seem to have improved overall. Although tumor stage 
is consi dered to be the most informative prognostic 
factor, little is known about the underlying molecular 
mechanisms of renal carcinogenesis.
The most common histological subtypes of RCC 
include clear cell (80%), papillary (> 10%), and chro-
mophobe (< 5%) carcinomas. These histological sub-
types are genetically and biologically different [3, 4]. 
Many genes and signaling pathways are known to be 
involved in RCC initiation and progression [5]. However, 
until today no tumor suppressor gene, which malfunc-
tion could be responsible or at least contributing to the 
development of clear cell renal cell carcinoma (ccRCC) 
has been identified. Several potential candidates were 
proposed, such as VHL (von Hippel Lindau), FHIT (fragi-
le histidine triad), TTRC1 (two-three-renal-cancer-1), 
DUTT1 (deleted in U-twenty twenty), locus NCR-1 (non 
papillary renal cell carcinoma 1), and RASSF1A (RAS 
association family 1) [6–9].
Papillary RCCs are characterized by trisomies 
(chromosomes 3q, 7, 12, 16, 17, and 20) and loss of the 
Y chromosome [10]. Chromophobe RCCs are charac-
terized by monosomy of multiple chromosomes (1, 2, 6, 
10, 13, 17, and 21). Clear-cell RCCs are characteri zed by 
loss of genetic material on the chromosomes 3, 8, 9, 10. 
Fifty percent of clear-cell RCCs show somatic mutations 
of VHL gene, and, moreover, the 10% to 20% of these 
tumors show inactivation of the VHL gene [11]. Loss 
of heterozygosity on chromosomes 8p or 9p provides 
prognostic significance in patients with locally advanced 
ccRCC and PTEN/MMAC1 (chromosome 10) inactiva-
tion that may play a role in the ccRCC progression [12]. 
However, these molecular markers have not yet gained 
general use in RCC diagnostics and prognosis.
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Renal cell carcinoma (RCC) is the most common malignant tumor of kidney associated with the worst clinical outcome. No mo-
lecular markers for RCC diagnostics and prognosis that could be applied in clinics were described yet. Large-scale screening of  3p 
human chromosome genes/loci in RCC and histologically normal tissues surrounding the tumors using NotI-microarray approach 
demonstrated that NKIRAS1 gene contained the largest percent of genetic/epigenetic changes in RCC tumor cells. Aim: To 
validate the results of NotI microarray analysis and study genetic, epigenetic changes, and the expression level of NKIRAS1 gene 
in human RCC samples. Methods: DNA and RNA were isolated from freshly-frozen renal tumors’ samples (n = 12) and from 
normal tissues surrounding the tumors. Epigenetic changes (methylation status) of NKIRAS1 were detected by bisulfite sequenc-
ing. Genetic changes and expression level were analyzed by Quantitative real-time PCR (qPCR) with SYBR Green. For relative 
quantification 2-ΔΔCP method was used. Nonparametric tests (Wilcoxon, Kruskal — Wallis and Mann — Whitney) were applied for 
statistical data analysis using the BioStat software. Results: NKIRAS1 expression was downregulated in 75% of RCC samples (9 of 
12) compared with surrounding normal tissue. High grade tumors (3 and 4) showed lower expression of NKIRAS1 at the mRNA 
level than tumors of low grade (1 and 2). No significant association was found between gene expression level and gender or age. 
Analysis of NKIRAS1 gene copy number was performed in 19 tumor samples. Changes in the copy number of NKIRAS1 gene were 
observed in 64% (9 of 14) of cRCC samples. 9 samples displayed ratio (< 0.85 and ≥ 0.35), thus were considered as hemizygous 
deletions. 3 samples showed ratio (> 0.85) and were considered as normal copy number. Changes in NKIRAS1 gene copy number 
were detected in all 3 benign oncocytomas, 1 papillary cancer and 1 sarcoma, where hemizygous deletion was observed. No changes 
in methylation status of NKIRAS1 were found in RCC. Conclusions: We have validated the results of NotI microarray analysis 
of NKIRAS1 gene in RCC. It was shown the decreased expression level of NKIRAS1 in this type of tumor.
Key Words: renal cell carcinoma, genetic and epigenetic regulation, chromosome 3, quantitative real time PCR, methylation status.
Received: May 10, 2010.
$These authors contributed equally to this work.
*Correspondence:  E-mail: vlakas@ki.se
Abbreviations used: ccRCC — clear cell renal carcinoma; NKIRAS1 — 
NF-B inhibitor interacting Ras-like 1; RCC — renal cell carcinoma; 
TBP — tata-box binding protein; VHL− von Hippel Lindau gene.
Exp Oncol 2010
32, 2, 71–75
ORIGINAL CONTRIBUTIONS
72 Experimental Oncology 32, 71–75, 2010 (June)
The most predominant type of RCC, clear cell car-
cinoma, was chosen for this study and the large-scale 
analysis of gene expression profiles was performed. 
Similar studies, reported by other groups earlier, have 
already identified some genes that might be useful 
for prognostic purposes or for classification of RCCs 
[13–15]. Consequently, relatively little is known about 
molecular expression profiles associated with tumor 
growth and metastatic progression of ccRCC.
The largest percent of genetic aberrations associ-
ated with ccRCC includes 3p loss or changes. DNA 
methylation/deletion is a key mechanism to inhibit the 
expression of tumor suppressor genes in cancer; hence 
DNA methylation/deletion markers have been applied 
in cancer risk assessment, early detection, prognosis, 
and prediction of response to cancer therapy.
Genetic/epigenetic changes could be investigated, 
using microarrays analysis. NotI microarrays that were 
recently developed by us, give the new possibilities for 
large scale study of deletion/methylation patterns in 
normal compared to pathological cells [16].
Using the NotI microarrays, we have found that 
a locus associated with the NF-B inhibitor interacting 
Ras-like 1 gene (NKIRAS1) had the largest percent of 
genetic/epigenetic changes, and exclusively in RCC 
[17–19]. The NKIRAS1 gene encodes a Ras-like protein 
that acts as a potent regulator of NF-kappa-B activity. 
[20–22]. Function of NKIRAS1 in carcinogenesis is 
unknown and its characterization can shed some light 
on the mechanism of epithelial cancer development.
In the present work we further analyzed the expres-
sion level, deletion and methylation status of the puta-
tive tumor suppressor gene NKIRAS1 in kidney cancers.
MATERIALS AND METHODS
Tissue samples. Frozen surgically removed tu-
mors and surrounding normal tissues were obtained 
from Kyiv National Urological Center (Kyiv, Ukraine). 
Tumors were histologically classified according to 
the WHO criteria by TNM classification. This series 
included 3 oncocytomas (benign), 18 conventional 
clear cell tumors (2 with sarcomatosis), 1 papillary 
tumor, and 1 sarcoma. The mean age of patients at 
diagnosis was 57.4 ± 11.6 (range 36–69 years), with 
a female/male ratio of 1.3. The present study was 
performed in accordance with the institutional Ethical 
Committee permission. All the samples enrolled in this 
study were processed anonymously.
Isolation of DNA and RNA. DNA was isolated 
using phenol-chloroform extraction. Total RNA was 
isolated from all fresh-frozen renal tumors and from 
normal tissues surrounding the tumors by homogeni-
zation with an acid guanidinium thiocyanate-phenol-
chloroform mixture as described [23]. Samples used 
for the qPCR reactions were of high molecular weight 
(unsheared band of undigested DNA visible on a 0.5% 
agarose gel) and pure from contaminations (an OD 
260/280 ranging from 1.6 to 1.8). From each RNA 
sample, 1 μg of total RNA was treated with DNAseI and 
reverse transcribed in duplicates, as well as negative 
controls without enzyme, using the reverse transcrip-
tase kit (Fermentas).
Methylation status. The methylation status of 
NKIRAS1 was determined in three selected samples by 
bisulfite sequencing as described earlier [24, 25]. Bisul-
fite treatment was performed using an EZ DNA Methyla-
tion Kit (Zymo Research Corporation, USA). PCR was 
carried out for 35 cycles comprising 30 s denaturation 
at 94 °C, 30 s annealing at 56 °C, and 1 min extension 
at 72 °C. The cycling started by 2 min denaturation at 
94 °C. The PCR products were purified using a DNA 
Clean and Concentrator Kit (Zymo Research Corpora-
tion) according to the manufacturer’s protocol, and the 
PCR products were cloned using a TOPO TA Cloning Kit 
for Sequencing (Invitrogen BV, Netherlands). Plasmid 
DNA was isolated using a Zyppy Plasmid Miniprep Kit 
(Zymo Research Corporation, USA). Sequencing was 
performed using a BigDye Terminator Cycle Sequenc-
ingReady Reaction kit v1.1 and ABI Prism 3100 Genetic 
Analyzer (Applied Biosystems, USA).
Primer design. Primers for gene NKIRAS1 were 
designed using Primer3 (http://frodo.wi.mit.edu/
primer3/) and PrimerQuest (http://eu.idtdna.com/Sci-
tools/Applications/ Primerquest/), and Oligo6.24 pro-
gram. For genomic sequence following primers were 
used: forward 5’-cgagaggtgagagagttggc-3’, reverse 
5’-tgcgtgaaacaaacctgttct-3’. For mRNA detection 
following primers were used: forward 5’-ctttcaaagagt-
ggagcttctg-3’, reverse 5’-tttccgatctgtaacagtcacc-3’. 
Primers for mRNA detection were selected to span at 
least one big intron (more than 1kb).
Expression level analysis. Reactions were per-
formed using SYBR Green. TBP was used as a reference 
gene [26]. Each qPCR reaction comprised 12.5 μl 2x 
SYBR Green PCR Master Mix (Fermentas), forward and 
reverse primer at optimized concentrations of 400 nM, 
10 ng/μl cDNA template and sterile water up to a final 
volume of 25 μl. The qPCR reactions were performed 
using Bio-Rad iQ5. The reaction profile was: initial step, 
72 °C for 2 min, denaturation 95 °C for 10 min, then 
35 cycles of denaturing at 95 °C for 20 s, annealing at 
60 °C for 20 s and extension at 72 °C for 40 s.
To generate standard curves for the selected pri-
mers and the reference primers a log10 dilution series 
of cDNA was prepared at concentrations ranging from 
1 ng to 100 ng. Reference gene TBP was previously 
found to be stably expressed in renal tumors. Each 
cDNA sample was analyzed in triplicate by real-time 
PCR, and detected with SYBR Green Master Mix. 
Each qPCR experiment contained duplicates of the 
notemplate-controls and patient samples. Quantifica-
tion was based on the increased fluorescence, which 
was measured and recorded using the Bio-Rad iQ5.
Copy number analysis. Quantitative real-time 
PCR (qPCR) was used for the quantification of marker 
copy numbers and has been shown to be precise 
enough to discriminate between two and one allele 
copies. The parameter CP (threshold cycle) is defined 
as the cycle number required for dye fluorescence to 
become higher than background fluorescence level. 
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Reactions were performed using SYBR Green and de-
tected with SYBR Green Master Mix (Fermentas) with 
similar reaction conditions as for expression analy-
sis. The method is based on the inverse exponential 
relationship that exists between initial quantity (copy 
number) of target sequence copies in the reactions 
and corresponding CP determinations — the higher 
the starting copy number of DNA target the lesser the 
CP value. This method was used to determine target 
sequence copy number in tumor DNA sample relative 
to the normal DNA from the same patient (calibra-
tor) and relative to an endogenous control sequence 
(reference) — TBP. Quantification was based on the 
increased fluorescence, which was measured and re-
corded using the Bio-Rad iQ5. According to histology 
analysis contamination of tumour samples with normal 
stroma and lymphocytes can reach up to 30–40%. 
Therefore, alleles were taken as homozygously deleted 
if the highest value of calculated range was below 
0.5 and hemizygously deleted if this value was below 
1.0. An allele was considered as amplified/multiplied 
if the lowest value of the range was over 1.0 [27].
Data analysis. Copy numbers in NKIRAS1 gene 
and its expression level was estimated by the 2-ΔΔCP 
method of relative quantification [28]. The relative ex-
pression ratio (R) of a target gene is calculated based 
on E and the CP deviation of an unknown sample versus 
a control, and expressed in comparison to a reference 
gene. For the ΔΔCP calculation to be valid, two im-
portant parameters must be considered beforehand. 
First, the efficiency of a given PCR amplification must 
be close to 100%, and second, the relative efficiency 
must be optimal. That is the amplification efficiencies of 
the target and reference genes must be approximately 
equal. PCR efficiencies (E) were calculated from the 
given slopes, according to the equation:
E = (10(-1/slope) – 1) × 100,
where E = 100 corresponds to 100% efficiency. Plots of 
the log DNA and cDNA dilutions vs ΔCP were made for 
each primer pair. Also for every reaction efficiency was 
calculated using sigmoidal and exponential models 
from qPCR package [29]. Further calculations were 
performed using Microsoft Excel. The range given for 
the probes was determined as E-ΔΔCP with ΔΔCP + S 
and ΔΔCP-S, where s is the standard deviation of the 
ΔΔCP value.
Statistical analysis. Nonparametric Wilcoxon test 
was used to compare mRNA expression of target and 
reference genes for the same sample. Then groups 
of samples were compared in respect to average 
level of mRNA decrease (LDav) and the frequency 
of decrease (FD). The LD was calculated as 1/R and 
reflects the n-fold factor by which the mRNA content 
decreased in the tumor compared to normal tissue. 
Nonparametric Kruskal — Wallis and Mann — Whitney 
rank-sum tests were used to test mRNA differences 
(both LDav and FD) for each target gene and with and 
without metastases. Nonparametric Spearmen’s cri-
terion was used to calculate the coefficient of correla-
tion between the levels of mRNA decrease (LDav) for 
each set of pairs of target genes. P-values < 0.05 were 
considered statistically significant. All statistical proce-
dures were performed using the BioStat software [30].
RESULTS AND DISCUSSION
NotI microarray approach allows the search for 
hemizigous deletion/methylation that can indicate 
a reduction or loss of expression of the certain genes. 
Previously, we have found changes in 137 of 181 NotI 
clones from human chromosomes 3 [17]. Heterozygous 
deletion/methylation events were observed most fre-
quently (428 cases); amplifications (24 cases) and ho-
mozygous deletion/methylation events (24 cases) were 
observed rarely. NotI microarray data analysis produced 
a profile of the changes in chromosome 3 genes/loci in 
the epithelial cancer samples. Among them, 27 genes/
loci showed changes in more than 30% of samples.
To validate NotI microarray results we have chosen 
the NF-B inhibitor interacting Ras-like 1 (NKIRAS1) 
gene that showed the highest percentage of genetic/
epigenetic changes. Gene NKІRAS1 is localized in 
3p24.2 locus on the human chromosome 3, which 
has the greatest amount of changes in epithelial can-
cers. Thus, 78% of cases demonstrated hemizigous 
deletion/methylation in the NotI locus associated with 
NKIRAS1 gene [17].
We selected several samples with genetic/epige-
netic changes for bisulphite sequencing and found 
an absence of DNA methylation in all samples, both in 
tumor and normal tissue (data not shown). To explain 
the high percent of changes obtained by NotI microar-
ray approach we measured the expression level and 
estimated the copy number of NKIRAS1 gene.
Significant (from 2 to 94 fold) decrease of the mRNA 
level (LD) of gene NKIRAS1 was observed in 75% 
of RCC samples (9 of 12, P < 0.002) in comparison 
to surrounding normal tissue (Table 1). TBP expres-
sion level was found to be constant in tumor and nor-
mal renal tissue. While no significant association was 
found between gene expression level and gender or 
age, it should be pointed out that NKIRAS1 expres-
sion correlated with histological grade. Thus, tumors 
of grade 3–4 had lower NKIRAS1 mRNA level than 
tumors of grade 1–2 (Figure).
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Figure. NKIRAS1 expression (n = 12) in renal cell carcinoma
Analysis of NKIRAS1 copy number was performed in 
19 samples (3 benign oncocytomas, 1 papillary cancer, 
1 sarcoma, and 14 ccRCCs), using qPCR  (Table 2). 
NKIRAS1 copy number decrease was observed in 
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64% (9 of 14) of cRCC samples: 9 samples displayed 
ratio < 0.85 and ≥ 0.35 and were conside red as 
hemizigous deletions. 3 samples had ratio > 0.85 and 
were considered to have unmodified copy number sta-
tus. Copy number changes were found in all 3 benign 
oncocytomas, 1 papillary cancer, and 1 sarcoma, where 
hemizigous deletions were observed. All these data 
suggest that NKIRAS1 gene could be involved in the 
carcinogenesis as a tumor suppressor gene.
The NKIRAS1 gene encodes a Ras-like protein that 
acts as a potent regulator of NF-kappa-B activity. Func-
tions of NKIRAS1 in carcinogenesis are still unknown. 
Mutations of other members of the Ras gene family 
(HRAS, KRAS2 or NRAS) are identified in approximately 
of 15% of human neoplasm cases [31]. Here we de-
scribe a novel member of this family which is associated 
with tumor growth and metastasis in epithelial cancer.
We have reported earlier that the CpG islands in 
the ITGA9 gene/locus were homozygously methy-
lated in one of the tissue samples, heterozygously 
methylated in the second sample, and unmethylated 
in the third sample from colorectal cancer [32]. These 
results correlated with the microarray results. The ratio 
of the hybridization signal intensity for tumor/normal 
tissues was 0.2, 0.55 and 0.97 for the three samples. 
No methylation of CpG islands was revealed for the 
corresponding normal tissues as well as no deletions 
were found. Our work demonstrated that the NotI 
microarray produces valuable data for analysis. The 
NotI microarray protocol might be useful as a primary 
screening method due to its ability to determine the 
global genetic/epigenetic changes in a genome. This 
may lead to the subsequent selection of gene candi-
dates that may participate in carcinogenesis.
In summary, we have found that NKIRAS1 is down-
regulated in malignant renal tumors and copy number of 
NKIRAS1 gene is decreased in RCC. Due to the results 
of NotI microarray analysis NKIRAS1 was selected for 
further investigation as a gene with the highest number of 
genetic alterations in epithelial tumors. We plan to analyze 
the association of NKIRAS1 expression with the age of pa-
tients, and perform further studies to test if  NKIRAS1 gene 
expression could be regarded as dia gnostic marker for 
RCC. The function of this protein in the development of 
renal cancer should be elucidated further.
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